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ABSTRACT
We estimate the medical cost per life-year gained from increased utilization of HIV drugs
by estimating the impact of increased drug utilization on the life expectancy and drug and hospital
expenditure  of  HIV/AIDS  patients,  using  aggregate  (U.S.  national-level)  data  for  the  period
1982-2001. We use IMS Health data on the aggregate number of and expenditure on HIV drug
prescriptions, the CDC’s AIDS Public Information Data Set, and data from AHRQ’s Nationwide
Inpatient Sample.
Estimates of mortality models imply that actual life expectancy of HIV/AIDS patients in
2001 was 13.4 years higher than it would have been if the drug utilization rate had not increased
from its 1993 level. Estimates of a model of hospital discharges imply that increased utilization of
HIV drugs caused hospital utilization to decline by .25 to .29 discharges per person per year during
the period 1993-2001. Medical cost per additional life-year is estimated to have been $17,175.
Treatments that cost this amount are widely considered to be cost-effective. The consistency
of this estimate with those from previous studies suggests that analysis of aggregate data may be a
useful alternative or additional approach to evaluating the cost-effectiveness of new treatments.
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Introduction 
 
Between 1993 and 2000, inflation-adjusted expenditure on HIV drugs per person living 
with AIDS increased more than fivefold, from about $1700 to about $9000.  This was largely 
attributable to substantial HIV drug innovation during this period: the number of FDA-approved 
HIV drug classes tripled (from 1 to 3), and the number of FDA-approved HIV drugs increased 
from 3 to 17 [1]. 
We will show that, during the same period, the number of hospital admissions for HIV 
infection per person living with AIDS declined 67%, and the five-year survival rate of people 
diagnosed with AIDS increased from 3% to 54%.  How much of the decline in the hospitalization 
rate, and increase in the survival rate, can be attributed to the large increase in HIV drug 
utilization?  To determine the incremental cost-effectiveness of these drugs, we need answers to 
these questions. 
Previous studies have used a variety of methods to estimate the clinical benefits and cost 
effectiveness of HIV/AIDS drugs.  Freedberg et al [2] developed a mathematical simulation 
model of HIV disease, using the CD4 cell count and HIV RNA level as predictors of the 
progression of disease. They derived clinical data from major clinical trials, including the AIDS 
Clinical Trials Group 320 Study, and data on costs from the national AIDS Cost and Services 
Utilization Survey and the Red Book.  They found that for patients similar to those in the AIDS 
Clinical Trials Group 320 Study (mean CD4 cell count, 87 per cubic millimeter), life expectancy 
adjusted for the quality of life increased from 1.53 to 2.91 years, and per-person lifetime costs 
increased from $45,460 to $77,300 with three-drug therapy as compared with no therapy. The 
incremental cost per quality-adjusted year of life gained, as compared with no therapy, was 
$23,000. On the basis of additional data from other major studies, the cost-effectiveness ratio for 
three-drug therapy ranged from $13,000 to $23,000 per quality-adjusted year of life gained. They   4 
concluded that treatment of HIV infection with a combination of three antiretroviral drugs is a 
cost-effective use of resources. 
Duggan and Evans [3] used individual-level pharmacy and medical claims data on about 
10,000 California Medicaid recipients diagnosed with HIV/AIDS to estimate the effect of HIV 
antiretroviral (ARV) treatments on longevity and long-term health care spending during the 
period 1993-2003.  Approximately half of all AIDS patients in the U.S. are enrolled in Medicaid.  
They accounted for the fact that patients taking ARVs are significantly less healthy than the 
average patient in their sample. Their findings demonstrated that the increase in the use of four 
drugs approved by the FDA in late 1995 and early 1996 was responsible for more than 90 percent 
of the drop in the mortality rate from 1995 to 1998. Despite the entry of more than a dozen drugs 
since these four, mortality rates have remained virtually unchanged. They found that the use of 
the new drugs led to a threefold increase in lifetime Medicaid spending due to their high cost and 
the resulting increase in life expectancy. Despite this, the new treatments were cost-effective, 
with the average additional cost in Medicaid spending per life-year saved equal to $23,000. 
In this paper, we use a third approach to estimate the clinical benefits and cost 
effectiveness of HIV/AIDS drugs: estimation of econometric models of mortality and 
hospitalization rates of HIV/AIDS patients using aggregate (U.S. national-level) time-series data 




We will estimate the relationship in the population of HIV/AIDS patients between the HIV 
drug utilization rate and both (1) the mortality rate and (2) the HIV hospitalization rate.  First we 
will explain how these three variables were measured.  Then we will specify the relationships to 
be estimated.   5 
Mortality rate.  The mortality rate is the number of deaths in a period divided by the average 
number of people alive during the period.  It can be estimated during the period 1981-2001 from 
the CDC’s AIDS Public Information Data Set [4].  AIDSPIDS contains two types of data: micro 
and macro.  The micro data set contains one record for each AIDS case reported to CDC during 
the period 1981-2001.   It reports the month of diagnosis of the person’s first AIDS-indicator 
opportunistic condition.  It also indicates whether the CDC was notified that this patient died by 
the end of 1999, but to protect confidentiality, it does not report the date of death. 
The macro data set provides frequencies of AIDS cases, by period (half-year) of diagnosis 
and period of death.  For example, it reveals that 264 people diagnosed with AIDS in the first half 
of 1988 died in the second half of 1992.   
The CDC expanded its AIDS surveillance definition on January 1, 1993 to include all HIV-
infected adults and adolescents who had less that 200 CD4
+ T-lymphocytes/µL or a CD4
+ T-
lymphocyte percent of total lymphocytes less than 14, or who have been diagnosed with 
pulmonary tuberculosis, invasive cervical cancer, or recurrent pneumonia [5].  This revision had a 
substantial impact on the number of reported cases: the number of reported cases increased from 
47,293 in 1992 to 104,759 in 1993.  But to measure trends over time using a constant case 
definition, CDC developed methods that estimated incidence of 1987 or 1993 definition 
opportunistic infections for cases that met only the 1993 immunologic (CD4
+) criteria.  As a 
result, the 1993 expansion of the AIDS case definition had only a small, transitory effect on the 
estimated number of diagnosed cases: the number of diagnosed cases was 79,657 in 1992 and 
79,879 in 1993.   
Let  
N_DIAGj = the number of people first diagnosed with AIDS in year j 
N_DIEDj = the number of deaths from AIDS in year j 
These data allow us to calculate the number of AIDS patients alive at the beginning of period t 
(N_ALIVEt) and the mortality rate during period t (MORT_RATEt), as follows:   6 
N_ALIVEt = Sj=1
t-1 (N_DIAGj - N_DIEDj) 
MORT_RATEt = N_DIEDt / ((N_ALIVEt + N_ALIVEt+1)/2) 
The top part of Figure 1 displays data on the AIDS mortality rate.  We computed the annual 
mortality rate from semiannual data as follows: a = (1 – (1 – s)
2), where a denotes the annual 
mortality rate and s denotes the semiannual mortality rate. 
The CDC [6] publishes data on the U.S. HIV/AIDS mortality rate; Lai et al [7] used these 
data to compute the potential gains of life expectancy due to the elimination or reduction of 
HIV/AIDS deaths.  The CDC’s HIV/AIDS mortality rate (CDC_RATE) is defined as follows: 
 
CDC_RATE = N_DIED / POP 
 
where POP = population.  The CDC’s mortality rate (the unconditional probability of dying from 
HIV/AIDS) is the product of two variables: the probability of dying from HIV/AIDS, conditional 
on having HIV/AIDS, and the probability of having HIV/AIDS: 
CDC_RATE = (N_DIED / PREV) * (PREV / POP)  
                      =    MORT_RATE    * (PREV / POP)  
where PREVt = (N_ALIVEt + N_ALIVEt+1) / 2. 
Since we want to examine the relationship between the HIV drug utilization rate and the mortality 
rate in the population of HIV/AIDS patients, we will analyze data on the conditional mortality rate 
(MORT_RATE), rather than on the CDC’s unconditional mortality rate. 
The lower part of Figure 1 displays data on the percentage change in the AIDS mortality 
rate.  Before 1987, when the first HIV drug was introduced, the mortality rate was in the 60-70% 
range, and was not declining.  From the first half of 1987 to the second half of 1995, it declined at 
the rate of 6.1% per half year.  From the second half of 1995 to the first half of 1998, it declined 
four times as rapidly--at the rate of 24.8% per half year.  From the first half of 1998 to the first 
half of 2001, it declined less rapidly--at the rate of 9.0% per half year.     7 
We compared mortality rates in 1994, 1997, and 2000 derived from AIDSPIDS with 
corresponding rates reported by Duggan and Evans [3, Table 2] from the California Medicaid 
sample.  The mortality rates in 2000 differ by only 10%, and both series indicate much more 
rapid decline during 1994-1997 than during 1997-2000.  However, the AIDSPIDS series exhibits 
more rapid decline: the ratio of the 1994 to the 2000 mortality rate is 6.25 for AIDPIDS, vs. 4.42 
for the California Medicaid sample. 
Survival functions for 1993 and 2000 are depicted in Figure 2.  They demonstrate the 
dramatic reduction in mortality during the 1990s. 
The average age of people diagnosed with AIDS tended to increase over time.  Before 
1985, over half of people diagnosed were under 35.  After 1999, less than 30% of people 
diagnosed were under 35.  In general, mortality rates increase with age, so the increase in age at 
diagnosis may make the decline in mortality even more striking.  However, it is possible that the 
disease progresses less rapidly in older patients than it does in younger patients, so the decline in 
the age-adjusted mortality rate could be smaller than the decline in the crude mortality rate.  
Although we have time-series data on the age distribution of people diagnosed with AIDS, we do 
not have data on the age distribution of people living with AIDS, so we can’t make an explicit 
adjustment for this.  However, the data indicate that the age distribution of people diagnosed with 
AIDS shifted at a fairly steady rate, so the estimation procedure we will use (described below), 
which involved first-differencing the data, may adequately control for the effect of changes in the 
age distribution of people living with AIDS. 
Life expectancy.  Our goal is to assess the impact of changing HIV drug utilization on 
the life expectancy of HIV/AIDS patients.  The concept of life expectancy we use is the one used 
by the National Center for Health Statistics [8] to calculate the official government estimates of 
U.S. life expectancy.  It is based on the “period life-table” (as opposed to the “cohort life-table”) 
method.   The period life table presents what would happen to a hypothetical (or synthetic) cohort 
if it experienced throughout its entire life the mortality conditions of a particular period in time.    8 
The period life table renders a “snapshot” of current mortality experience, and shows the long-
range implications of a set of duration-specific death rates that prevailed in a given year.   
Under certain assumptions, there is a very simple relationship between life expectancy 
and the crude mortality rate.  If the survival distribution function is exponential, i.e. the hazard 
rate is independent of duration, life expectancy is simply the reciprocal of the crude mortality 
rate.  For example, if the crude mortality rate is 5%, then life expectancy is 20 years.   
Analysis of the AIDSPIDS data revealed that the hazard rate is not independent of 
duration: the hazard rate is strictly decreasing with respect to duration of illness.  For example, a 
person is 17% less likely to die in the third year after diagnosis than in the first year after 
diagnosis, and is 35% less likely to die in the fifth year than in the first year.  This may be partly 
or wholly attributable to heterogeneous severity of (or vulnerability to) illness: individuals with 
less severe cases are both more likely to survive until the beginning of year t, and less likely to 
die during year t, conditional on survival until the beginning of year t.  We therefore also 
computed estimates of life expectancy from survival functions that are more flexible than the 
exponential (e.g. the Weibull or the Gamma)￿￿￿We found that these estimates of life expectancy 
were fairly similar to those produced by the much simpler approach (i.e. computing the reciprocal 
of the mortality rate), despite evidence that the hazard rate is not independent of duration.  
Therefore, like Duggan and Evans [3], we will estimate life expectancy by the reciprocal of the 
mortality rate: 
LEt = 1 / MORT_RATEt = ((N_ALIVEt + N_ALIVEt+1)/2) / N_DIEDt  
Drug utilization rate.  The drug utilization rate (rxt) is the ratio of the number of 
prescriptions (Rx’s) for HIV drugs to the number of people living with AIDS.   
rxt = N_RXt / ((N_ALIVEt + N_ALIVEt+1)/2) 
     = HIV rx’s per person living with AIDS in period t 
where N_RXt = the number of prescriptions (Rx’s) for HIV drugs in period t.  (This refers to any 
prescription during the time period considered (i.e., consecutive as well as simultaneous)).    9 
Data on the numerator of this ratio were obtained from IMS Health.  Different purchasers 
incur different expenditures for the same drug in the U.S.  This is particularly true for HIV drugs, 
where the major payers are state Medicaid and AIDS Drug Assistance Programs, who receive 
substantial receive discounts and manufacturer rebates.  These discounts and rebates are reflected 
in the IMS data: the data reflect actual transaction prices, not list prices such as “average 
wholesale price”. 
Data on the denominator were computed from AIDSPIDS.  Data on HIV drug 
expenditure, quantities, and prices, 1987-2003, are shown in Table 1.  Figure 3 shows average 
drug utilization during the period 1981-2001.  No HIV drugs were consumed (or approved) until 
1987.  From 1987 to 1992, the number of HIV Rx’s per person increased steadily, reaching about 
3.7 per half-year in 1992.  From 1992 to 1995, average drug utilization declined, to about 2.2 HIV 
Rx’s per half-year.  From the second half of 1995 to the second half of 1997, average drug 
utilization quadrupled, from 2.55 to 10.29 per half-year.  Despite the FDA approval of five new 
drugs during 1998-2000, it stayed close to ten through the first half of 2001. 
Hospitalization rate.  We obtained annual data on inpatient hospitalizations for HIV 
infections during the period 1993-2002 from the Nationwide Inpatient Sample (NIS).  NIS is the 
largest all-payer inpatient care database in the United States. It contains data from approximately 
7 million hospital stays.  NIS is the only national hospital database with charge information on all 
patients, regardless of payer, including persons covered by Medicare, Medicaid, private 
insurance, and the uninsured. NIS 2002 contains all discharge data from 995 hospitals located in 
35 States, approximating a 20-percent stratified sample of U.S. community hospitals.   NIS data 
are available from 1988 to 2002, and HCUP publishes state- and national-level data for the period 
1993-2002.  The number of States in the NIS has grown from 8 in the first year to 35 currently.    
Data on inpatient hospitalizations for HIV infections (Major Diagnostic Category 25) 
during the period 1993-2002 were downloaded directly from the HCUPnet website [9] and are 
presented in Table 2.  We defined the HIV hospitalization rate as follows:   10 
hospt = N_HOSPt / ((N_ALIVEt + N_ALIVEt+1)/2) 
         = inpatient hospital discharges for HIV infections per person living with AIDS in 
year t 
where N_HOSPt = the number of inpatient hospitalizations for HIV infections in period t 
Econometric specification.  We will estimate the relationship in the population of 
HIV/AIDS patients between the HIV drug utilization rate and both (1) the mortality rate and (2) 
the HIV hospitalization rate.   The mortality analysis will be based on semiannual data for the 
period 1982:2-2001:2 (N = 39).  The hospitalization analysis will be based on annual data for the 
period 1993-2001 (N = 9).   
We will examine the relationship between the logarithm of the mortality rate and the HIV 
drug utilization rate.  This seems appropriate because the mortality rate is bounded between zero 
and one, and also because the mortality rate changed by a factor of 18 over the sample period.  
We don’t use the logarithm of the HIV drug utilization rate because this variable was equal to 
zero before 1987.  This semi-logarithmic specification is predicated on the hypothesis of 
diminishing returns: equal successive increases in the HIV drug utilization rate result in declining 
successive (absolute) reductions in the mortality rate.   We show below that this specification 
seems to fit the data quite well. 
The hospitalization rate changed far less during 1993-2001—by a factor of 3.8—than the 
mortality rate changed during 1982:2-2001:2.  It is also not bounded from above.  We estimated 
models of both the hospitalization rate and the logarithm of the hospitalization rate.  The 
estimates had similar implications; the former model seemed to fit the data slightly better, so we 
will report estimates of that model.   
Many time series variables are characterized by unit roots.  A variable y is said to have a 
unit root if p = 1 in the autoregressive equation yt = g + p yt-1 + et.  As Greene [10, p. 846] 
observes, the regression of one variable characterized by a unit root on another variable 
characterized by a unit root “is virtually certain to produce a significant relationship, even if the   11 
two are, in fact, independent.”  He notes that under these circumstances, “the case for first 
differencing or detrending is compelling” [10, p. 847].   
We estimated autoregressive equations for each of the three variables.  The results are 
shown in Table 3.  These estimates suggest that all three variables have, or nearly have, unit 
roots.  (The estimate of p in the log(mort) equation is significantly greater than one.)  We will 
therefore estimate relationships between first differences, rather than levels, of the variables.   
Although the first difference of log(mort) is not stationary—the slope of the regression of 
Dlog(mort) on a time trend is negative and significant—the first difference of the HIV drug 
utilization rate appears to be stationary.  Greene [10, p. 844] observes that further differencing of 
time-series can increase rather than decrease autocorrelation. 
Hence, we will estimate the following model of the mortality rate: 
(1)  Dln(mort_ratet) = d + b Drxt + ut            
where  
mort_ratet = the crude mortality rate in period t 
            rxt = HIV rx’s per person living with AIDS in period t 
and D denotes the change from the previous period. 
Eq. (1) embodies the assumption that changes in the rate of mortality decline are related 
only to contemporaneous changes in average drug utilization.  It is quite possible that changes in 
mortality also depend on lagged changes in average drug utilization.  To allow for this possibility, 
we will also estimate models like: 
(2)  Dln(mort_ratet) = d + b Drxt + b-1 Drxt-1 + b-2 Drxt-2 + ut      
In this model, the long-run effect of drug utilization (i.e., the effect of a sustained increase in rx) 
is the sum of the coefficients, (b + b-1 + b-2).     12 
If drug utilization is exogenous with respect to mortality, changes in mortality should 
depend on current and past changes in drug utilization, but not on future changes.  We can test the 
exogeneity of drug utilization by testing whether b+1 = 0 in the model 
(3)  Dln(mort_ratet) = d + b+1 Drxt+1 + b Drxt + b-1 Drxt-1 + b-2 Drxt-2 + ut     
We will estimate the following model of the hospitalization rate: 
(4)  Dhospt = d + b Drxt + ut              
where 
  hospt = inpatient hospital discharges for HIV infections per person living with AIDS in 
year t. 





Mortality results.  Figure 4 shows the time series plots of Dln(mort_ratet) and Drxt.  It suggests 
that changes in the rate of mortality decline were closely related to changes in average drug 
utilization.   
Estimates of regressions of Dln(mort_ratet) on current, lagged, and/or future changes in 
drug utilization (eqs. 1-3) are reported in Table 4.  All equations were estimated allowing for 
first-order serial correlation.  The Durbin-Watson statistics indicate that the residuals are 
reasonably well-behaved.   
Column 1 shows the regression of Dln(mort_ratet) on Drxt and Drxt-1.  The coefficients on 
both variables are negative and highly significant.  The magnitude of b-1 is 50% larger than the 
magnitude of b, indicating that￿ an increase in drug utilization reduces the mortality rate 50%   13 
more after six months than it does immediately.  The sum of the coefficients is -0.10: one 
additional prescription per person living with AIDS reduced the mortality rate by about 10%.   
In column 2 we also include a time trend, to further guard against the possibility of 
spurious correlation.  Although the trend is significant, its inclusion has virtually no effect on the 
estimated b’s.   
In column 3 we add Drxt-2 to the equation, but exclude the time trend.  The coefficient on 
Drxt-2 is significant at the 6% level; adding it increases the magnitude of the sum of the b’s by 
19%.  In column 4 we include the time trend.  The coefficient on Drxt-2 is significant at the 10% 
level; the sum of the b’s is now -.11.   
Finally, in column 5, we include Drxt+1, the change in drug utilization in the next period.  
The coefficient on Drxt+1 is far from statistically significant (p-value = 0.66), lending support to 
the exogeneity of drug utilization.   
These estimates can be used to calculate how much higher the mortality rate would have 
been in 2001 if the drug utilization rate had not increased up until that point.  The calculations are 
summarized in Table 5.  Between 1993 and 2001, the average semiannual rate of drug utilization 
increased by 6.5, from 2.9 to 9.4 prescriptions.  The estimates in column 4 imply that this reduced 
ln(mort_rate) by 0.71.  In other words, ln(mort_rate2001) would have been 0.71 higher if the rate of 
drug utilization had not increased since 1993; mort_rate2001 would have been 2.03 (= exp(0.71)) 
times as high as it actually was.  The actual value of mort_rate2001 was 3.8%, so the predicted 
value, if drug utilization had not increased after 1993, is 7.7% (= 2.03 * 3.8%).  As discussed 
above, life expectancy may be approximated by the reciprocal of the mortality rate.  This implies 
that actual life expectancy in 2001 was 13.4 (= 26.3 – 12.9) years higher than it would have been 
if the drug utilization rate had not increased from its 1993 level.  These data suggest that about 
60% of the total 22.6-year increase in life expectancy during 1993-2001 is attributable to the 
increase in drug utilization.   14 
Hospitalization results.   Figure 5 shows annual data on changes in drug and hospital utilization 
during 1994-2002.  This chart suggests that there is a strong inverse relationship between these 
variables.   
Estimates of eq. (4) are presented in Table 6.  Estimates of b and d are significantly 
different from zero, suggesting that the hospitalization rate is inversely related to the drug 
utilization rate, and that the hospitalization rate would have declined, even if the drug utilization 
rate had not increased.  From 1993 to 2001, the semiannual drug utilization rate increased by 6.33 
(from 2.88 to 9.21).  The estimates imply that this caused hospital utilization to decline by .25 to 
.29 discharges/year.  (The total decline in hospital utilization was 0.75 discharges per year).   
Now we will estimate the effect of increased HIV drug utilization and expenditure on overall 
medical expenditure per year and over the course of the patient’s remaining life.  First we will 
estimate actual expenditure per HIV patient in 2000.  Then we will estimate what expenditure per 
patient would have been in 2000 in the absence of any increase in drug utilization after 1993. 
Data on average inpatient and outpatient utilization and costs in 2000 are available from 
HIVnet [11].  Data on average prescription drug utilization and costs in 2000 are calculated in 
Table 1.  These figures are summarized in Table 7.   As shown in Table 1, from 1993 to 2000, 
mean drug expenditure per patient increased by $7356 (in 2001 dollars).  This was due to 
increases in both the average number and average price of prescriptions.  We estimate that the 
1993-2000 increase in drug utilization reduced the average number of hospital admissions per 
HIV patient in 2000 by 0.33.  (In the absence of the drug utilization increase, the number of 
hospital admissions (like the number of deaths) would have been double what it actually was.)  
Therefore the 1993-2000 increase in drug utilization reduced mean hospital expenditure in 2000 
by $3826.   About 52% (= $3826/$7356) of the increase in HIV drug expenditure appears to have 
been offset by a reduction in hospital expenditure.  
The increase in drug utilization may also have reduced outpatient costs: between 1991 
and 2000, the average annual number of outpatient visits per HIV patient declined from 41.0 to   15 
6.4.  (The 1991 figure was calculated from the AIDS Cost and Services Utilization Survey.)  But 
time-series data on outpatient visits are not available, so it is hard to know how much of this 
decline can be attributed to increased drug utilization.  For the moment, assume that increased 
drug utilization reduced hospital expenditure, but not outpatient expenditure.   
In this case, we predict that, if drug utilization had not increased from its 1993 level, 
average medical expenditure in 2000 would have been $10,247 (= $13,777 - $7356 + $3826).  As 
Table 8 shows, by combining these annual expenditure figures with the life expectancy figures 
derived earlier, we can compute actual vs. counterfactual lifetime medical expenditure.  In 2000, 
average medical expenditure per HIV patient was $13,777, and his life expectancy was 26.3 
years, so (undiscounted) lifetime medical expenditure is projected to be $362 thousand.  If drug 
utilization had not increased from its 1993 level, average medical expenditure in 2000 would 
have been $3530 lower, and life expectancy would have been 12.9 years, so lifetime medical 
expenditure would have been $132 thousand.  Medical cost per additional life-year is $17,175 (= 




This paper has assessed the impact of increased utilization of HIV drugs on the life 
expectancy, annual medical expenditure, and lifetime medical expenditure of HIV/AIDS patients, 
using aggregate (U.S. national-level) data for the period 1982-2001.   
Estimates of a mortality model implied that actual life expectancy in 2001 was 13.4 years 
higher than it would have been if the drug utilization rate had not increased from its 1993 level.  
About 60% of the total 22.6-year increase in life expectancy during 1993-2001 is attributable to 
the increase in drug utilization. 
Estimates of a model of hospital discharges implied that increased utilization of HIV 
drugs caused hospital utilization to decline by .25 to .29 discharges per person per year.  About   16 
one-third of the total decline in hospital utilization during 1993-2001 is attributable to the 
increase in drug utilization, and 52% of the increase in HIV drug expenditure appears to have 
been offset by a reduction in hospital expenditure.  
Two caveats apply to our hospitalization estimates.  First, the HCUP data on HIV 
hospital admissions may not be completely reliable: HIV hospital admissions were 
geographically concentrated in a few major urban centers, particularly in earlier years of the HIV 
epidemic, when HCUP also included data from fewer states.  Second, due to measurement error 
in estimating the number of HIV patients, our estimate of the reduction in hospital discharges is 
likely to be conservative.  Suppose that the number of patients living with AIDS is overestimated 
in year t (e.g. due to failure of AIDSPIDS to distinguish between people who remain alive and 
people who have died but whose date of death is unknown).  This would cause both hospt and rxt 
to be underestimated in year t, and induce a positive correlation between these two series.  
In 2000, average medical expenditure per HIV patient was $13,777, and his life 
expectancy was 26.3 years, so (undiscounted) lifetime medical expenditure is projected to be 
$362 thousand.  If drug utilization had not increased from its 1993 level, average medical 
expenditure in 2000 would have been $3530 lower, and life expectancy would have been 12.9 
years, so lifetime medical expenditure would have been $132 thousand.  Medical cost per 
additional life-year is $17,175.   
Increased drug utilization may have reduced outpatient as well as inpatient costs.  If there 
would have been twice as many outpatient visits in 2000 absent the post-1993 increase in drug 
utilization—12.8 rather than 6.4 visits per person—we estimate that cost per life-year is $16,007 
instead of $17,175.   
Our estimates of mean lifetime expenditure (both actual and predicted under 1993 drug 
utilization) are not discounted.  The estimates of Duggan and Evans are also not discounted.  To 
produce accurate estimates of discounted expenditure, one needs to project the course (or growth 
rate) of future annual medical expenditure over a patient’s remaining life, which is difficult to do.    17 
If the growth rate of annual medical expenditure exceeds the discount (interest) rate, then 
discounted expenditure exceeds undiscounted expenditure.  If the growth rate is lower than the 
discount rate, then discounted expenditure is lower than undiscounted expenditure.  It seems to us 
that the growth rate could be either higher or lower than the discount rate, so that undiscounted 
estimates need not either overstate or understate discounted estimates. 
These estimates are similar to those obtained in previous studies based on completely 
different methods.  Freedberg et al’s estimate of the (discounted) cost of three-drug therapy per 
quality-adjusted year of life gained, derived from a mathematical simulation model of HIV 
disease, ranged from $13,000 to $23,000.  Duggan and Evans’ (2005) estimate of medical cost 
per additional life-year, derived from individual-level pharmacy and medical claims data, was  
$23,000.  Both authors note that treatments that cost $23,000 per life-year gained are widely 
considered to be cost-effective.  Murphy and Topel [12] argue that the average value of a U.S. 
statistical life may be on the order of $150,000. 
The overall consistency of our estimates with those from previous studies suggests that 
analysis of aggregate data may be a useful alternative or additional approach to evaluating the 
cost-effectiveness of new treatments. 
Our estimates, and those by previous authors, do not account for a potentially important 
benefit of new HIV drugs: increased ability to work.  The data shown in Table 9, computed from 
the 1996-2001 waves of the Medical Expenditure Panel Survey [13], indicate that the percent of 
people with HIV who were unable to work due to illness has been declining.  The difference in 
percentages is significant at the 5.3% level.  Moreover, the measured improvement in ability to 
work may be underestimated because there were probably more early diagnoses of HIV between 
1996 and 1998, possibly leading to a higher proportion of HIV-infected individuals in the MEPS 
who knew that they were HIV-infected, were asymptomatic and were still able to work.  It is 
likely that increased drug utilization reduced inability to work among HIV patients.   
   18 
The HIV drugs already approved by the FDA may be either less or more cost-effective in 
the future than they have been in the past.  Increasing resistance to these drugs would clearly 
reduce their cost-effectiveness.    On the other hand, the patents on these drugs will eventually 
expire.   When they do, the cost-effectiveness of these drugs will increase dramatically, since 
drug prices typically decline by about 80% following patent expiration.  However, the impact of 
patent expirations on total HIV drug expenditures is likely to be reduced as newer drugs that are 
considered more effective or convenient or that have fewer side effects replace drugs closer to 
patent expiration. 
Forecasting the future trajectory of HIV/AIDS treatment and outcomes is difficult.  As 
the philosopher Soren Kierkegaard observed, "life must be lived forwards, but can only be 
understood backwards."  But there is reason to expect further progress in the future.  Just days 
ago the FDA approved a new product that may have a significant impact.  On July 12, 2006, the 
FDA approved Atripla Tablets, a fixed-dose combination of three widely-used antiretroviral 
drugs, in a single tablet taken once a day, alone or in combination with other antiretroviral 
products for the treatment of HIV-1 infection in adults. Atripla, the first one-pill, once-a-day 
product to treat HIV/AIDS, combines the active ingredients of Sustiva (efavirenz), Emtriva 
(emtricitabine) and Viread (tenofovir disoproxil fumarate). Bristol-Myers Squibb and Gilead 
Sciences have formed a joint venture to commercialize Atripla in the United States. The 
collaboration is the first of its kind in the field of HIV/AIDS. In certain territories, Merck holds 
the rights to efavirenz. All three companies will work together to ensure the product is available 
to patients and physicians. "The approval of Atripla simplifies the treatment regimen for HIV-1 
infected adults, and will potentially improve the ability of patients to adhere to treatment resulting 
in long-term effective control of HIV-1. This offers a particularly important advantage for 
patients in many countries that are most affected by the AIDS epidemic and will also have a 
major impact in the U.S.," said Dr. Andrew C. von Eschenbach, the Acting Commissioner of 
Food and Drugs.   19 
HIV/AIDS continues to be an active area of pharmaceutical R&D.  According to the U.S. 
government’s ClinicalTrials.gov website, which provides regularly updated information about 
federally and privately supported clinical research in human volunteers, at present, there are 557 
trials of HIV/AIDS drugs currently recruiting or planning to recruit patients; 1753 trials have 
been completed or are no longer recruiting patients.   
   20 
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Figure 4
Change in average drug utilization and
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Table 1 
HIV drug expenditure, quantities, and prices, 1987-2003 
                   
Year 
Total expend. 







































1987  $21,645,000  44,000  $492  0.64  $767  24,076  1.8  $899  $1,402 
1988  $94,413,000  155,000  $609  0.67  $912  37,825  4.1  $2,496  $3,737 
1989  $120,129,000  274,000  $438  0.70  $626  52,989  5.2  $2,267  $3,238 
1990  $118,242,000  395,000  $299  0.74  $406  69,566  5.7  $1,700  $2,303 
1991  $128,594,000  510,000  $252  0.77  $328  90,155  5.7  $1,426  $1,855 
1992  $219,567,933  881,954  $249  0.79  $314  120,792  7.3  $1,818  $2,295 
1993  $215,463,941  960,195  $224  0.82  $275  156,769  6.1  $1,374  $1,684 
1994  $187,382,573  854,331  $219  0.84  $262  185,057  4.6  $1,013  $1,210 
1995  $243,987,768  1,015,081  $240  0.86  $279  205,556  4.9  $1,187  $1,379 
1996  $730,378,758  2,870,875  $254  0.89  $287  226,366  12.7  $3,227  $3,642 
1997  $1,301,074,673  4,965,342  $262  0.91  $289  251,658  19.7  $5,170  $5,705 
1998  $2,122,480,573  5,497,208  $386  0.92  $420  277,265  19.8  $7,655  $8,317 
1999  $2,611,440,838  6,414,291  $407  0.94  $433  300,130  21.4  $8,701  $9,249 
2000  $2,830,025,097  6,551,441  $432  0.97  $444  321,948  20.3  $8,790  $9,040 
2001  $3,293,652,795  6,369,758  $517  1.00  $517  337,783  18.9  $9,751  $9,751 
2002  $3,608,326,800  6,923,830  $521  1.02  $513             
2003  $3,962,475,549  7,549,933  $525  1.04  $505             
                   
Sources: IMS; AIDSPIDS               
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Table 2 
   
Hospitalizations in Major Diagnostic Category 25 (HIV 
Infections), 1993-2002 
   
Year  Total number of discharges 
1993  159,566 
1994  167,599 
1995  198,752 
1996  163,115 
1997  124,120 
1998  123,250 
1999  111,548 
2000  102,910 
2001  89,931 
2002  92,791 
   
Source: http://hcup.ahrq.gov/HCUPnet.asp   27 
 
Table 3 
Estimates of autoregressive equations for the three variables 
         
y  log(mort)  rx  hosp  rx 
p  1.03939  1.00116  0.90565  0.81394 
std. err.  0.013  0.03163  0.14806  0.18351 
t-statistic  79.97  31.65  6.12  4.44 
p-value  <.0001  <.0001  0.0009  0.0044 
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Table 4 
Estimates of models of D D D Dln(mort_ratet) 
             
Column     1  2  3  4  5 
                    
Drxt+1                  
   estimate              0.004535 
   std. err.              0.0102 
   t-stat              0.44 
   p-value              0.6604 
                    
Drxt                  
   estimate  -0.0405  -0.0352  -0.0409  -0.0381  -0.0408 
   std. err.  0.012  0.0105  0.0114  0.009759  0.0115 
   t-stat  -3.37  -3.34  -3.58  -3.90  -3.56 
   p-value  0.0019  0.0021  0.0011  0.0005  0.0013 
                    
Drxt-1                  
   estimate  -0.0601  -0.0638  -0.055  -0.0537  -0.0554 
   std. err.  0.012  0.0107  0.0117  0.0109  0.0115 
   t-stat  -4.99  -5.98  -4.70  -4.91  -4.81 
   p-value  <0.0001  <0.0001  <0.0001  <0.0001  <0.0001 
                    
Drxt-2                  
   estimate        -0.0226  -0.0175  -0.0179 
   std. err.        0.0116  0.0101  0.0107 
   t-stat        -1.95  -1.74  -1.67 
   p-value        0.0595  0.092  0.1062 
                    
time (measured in days)                   
   estimate    
-





   std. err.     3.27E-06     3.47E-06  3.49E-06 
   t-stat     -4.70     -4.69  -4.31 
   p-value     <0.0001     <0.0001  0.0002 
                    
Intercept                              
   estimate  -0.0577  0.122  -0.051  0.1379  0.1274 
   std. err.  0.0126  0.0381  0.013  0.0406  0.0406 
   t-stat  -4.59  3.20  -3.93  3.40  3.14 
   p-value  <0.0001  0.003  0.0004  0.0019  0.0039 
                    
sum of current & lagged b's     -0.1006  -0.099  -0.1185  -0.1093  -0.1141 
                    
Durbin-Watson statistic     1.8461  1.8209  1.8729  1.9308  1.8371 
R
2     0.7853  0.8392  0.8173  0.872  0.8767   29 
 
Table 5 
Actual vs. predicted mortality rates and life expectancy 
     
   mortality rate  life expectancy 
2001 actual  3.80%  26.3 
2001 predicted, given 1993 drug util rate  7.70%  12.9 




Estimates of eqs. (4) 
   
Parameter estimates    
b b b b        -0.046 
Standard Error  0.013 
t Stat  -3.583 
P-value  0.012 
     
d d d d        -0.050 
Standard Error  0.024 
t Stat  -2.119 
P-value  0.078 
     
   
   
   
   
     
Regression Statistics    
Multiple R  0.826 
R Square  0.682 
Adjusted R Square  0.628 
Standard Error  0.061 
Observations  8 
     
Degrees of freedom    
Regression  1 
Residual  6 
Total  7 
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Table 7 
Average inpatient, outpatient and drug utilization and costs in 2000 
       
Category  mean no. of events  mean expend. per event  mean expend. 
inpatient  0.32  $11,722   $3,773  
outpatient  6.42  $189   $1,213  
drug  20.3  $432   $8,790  






Actual vs. counterfactual lifetime medical expenditure 
       
  
mean expend--
annual  life expectancy 
mean expend--
lifetime 
2000 actual  $13,777   26.3  $362,325  
2000 predicted 
if 1993 drug util.  $10,247   12.9  $132,185  






Percent of people with HIV who were unable to work due to illness 
     
Period 
% of persons with HIV who 
were unable to work 
because of illness  N 
1996-1998  54.3%  70 
1999-2001  38.0%  71 
 
 